Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-9231 for Body Parts MRI
NCT07275723Phase 3Completed
- Start
- Nov 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of HRS-9231 in vascular anomaly (2 arms). Primary endpoints: Lesion visualization score (border delineation) at Day 1, Lesion visualization score (internal morphology) at Day 1 and 1 more. Started Nov 2025; status: completed.
02
Drugs
HRS-9231
03
Conditions
vascular anomaly
Beyond the preview
Go deeper on NCT07275723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07275723.